- Home
- |
- Contact
- |
- Pharmacovigilance
- |
Welcome to
Chiesi group
Once again, Chiesi Group has been confirmed as the 1st Italian pharmaceutical company and the 3rd among the Italian companies in all segments, for patents applications, with a consolidated number of 42 first filings at the European Patent Office (EPO), according to the publication of the patenting trends for 2022[1].
An important milestone resulting from the Chiesi’s commitment to supporting the scientific progress necessary to improve the lives of people all over the world, developing its innovative capacity.
Generally, in 2022, Italy recorded an increase of +2.5% in the number of patent applications (in line with the European average) and of +3.2% in the number of patents granted at the European level. The percentage of increase becomes even more significant if we refer to the chemical-pharmaceutical sector, where there is a +12.3% compared to the applications filed in 2021.
[1] https://www.epo.org/about-us/annual-reports-statistics/statistics.html
